News

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.
Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...
THE new Food and Drug Administration (FDA) application procedures are expected to reduce the drug permit process by as much ...
The product, available in 200 mg, 400 mg, 600 mg, and 800 mg strengths, is the generic equivalent of Sumitomo Pharma ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on ...
A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...
Novo Nordisk said the Food and Drug Administration has accepted its submission of a new drug application for a Wegovy pill to treat obesity. The Bagsvaerd, Denmark, company said Friday that if the ...
Explore cutting-edge methods for detecting alcohol biomarkers and drugs of abuse using alternative sample matrices.